China API Facility Receives FDA Warning Letter
The agency sent a warning letter to Chongqing Pharma Research Institute Co., Ltd. citing data integrity violations.
FDA sent a warning letter to Chongqing Pharma Research Institute Co., Ltd. on Feb. 14, 2017 that summarized current good manufacturing practice (CGMP) deficiencies found at the company’s Chongqing facility during an inspection conducted from May 16–19, 2016. Inspectors found data integrity problems including failure to maintain laboratory testing data.
During the May 2016 inspection, FDA investigators found audit trails that showed the company had deleted chromatographic sequences and individual injections from computers and repeated analyses until acceptable results were maintained. Out-of-specification results were not investigated and only passing results were documented. “You relied on these manipulated test results and incomplete records to support batch release decisions,” the agency stated in the letter.
FDA requested that the company perform data integrity remediation and provide the agency with a comprehensive investigation of the data and reporting inaccuracies; a risk assessment of the potential effects of observed failures on the quality of product; and a management strategy that details a corrective action and preventive action plan.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
